157 related articles for article (PubMed ID: 35530285)
1. A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.
Li W; Zhou J; Zhang T; Tai Y; Xu Y; Bai Y; Jiang Y; Lu Z; Li L; Huang J; Pan Z; Wu X; Peng J; Lin J
Am J Cancer Res; 2022; 12(4):1648-1659. PubMed ID: 35530285
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary approach to the diagnosis and treatment of patients with potentially resectable colorectal cancer liver metastasis: results of a multicenter study.
Han L; Xue J; Wu X; Liang G; Wu Y; Guo F; Gao S; Sun G
Ann Palliat Med; 2022 Feb; 11(2):717-729. PubMed ID: 35249349
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
[No Abstract] [Full Text] [Related]
4. Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.
Peng J; Liu Y; Li W; Lin Y; Sun H; Pan Z; Wu X; Fan W; Lin J
Therap Adv Gastroenterol; 2021; 14():17562848211066206. PubMed ID: 34987612
[TBL] [Abstract][Full Text] [Related]
5. Estimating Efficacy of Conversion Therapy on Patients with Initially Unresectable Colorectal Cancer Liver Metastases by using MRI: Development of a Predictive Score.
Liu J; Tang W; Ye L; Miao G; Zeng M; Liu L
Acad Radiol; 2024 May; ():. PubMed ID: 38734578
[TBL] [Abstract][Full Text] [Related]
6. Methylated ctDNA predicts early recurrence risk in patients undergoing resection of initially unresectable colorectal cancer liver metastases.
Chen ZG; Ji XM; Xu YX; Fong WP; Liu XY; Liang JY; Tan Q; Wen L; Cai YY; Wang DS; Li YH
Ther Adv Med Oncol; 2024; 16():17588359241230752. PubMed ID: 38425989
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of total tumor volume reduction ratio in initially unresectable colorectal liver metastases after first-line systemic treatment.
He J; Li W; Zhou J; Sun H; Zhou C; Liu Y; Quan T; Fan W; Pan Z; Lin J; Peng J
Eur J Radiol; 2023 Aug; 165():110950. PubMed ID: 37437437
[TBL] [Abstract][Full Text] [Related]
8. Conversion therapy combined with individualized surgical treatment strategy improves survival in patients with colorectal cancer liver metastases.
Ma R; Li T
Int J Clin Exp Pathol; 2021; 14(3):314-321. PubMed ID: 33786148
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study.
Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS
Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145
[TBL] [Abstract][Full Text] [Related]
10. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
[TBL] [Abstract][Full Text] [Related]
11. Deep radiomics-based fusion model for prediction of bevacizumab treatment response and outcome in patients with colorectal cancer liver metastases: a multicentre cohort study.
Zhou S; Sun D; Mao W; Liu Y; Cen W; Ye L; Liang F; Xu J; Shi H; Ji Y; Wang L; Chang W
EClinicalMedicine; 2023 Nov; 65():102271. PubMed ID: 37869523
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
[TBL] [Abstract][Full Text] [Related]
13. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
[TBL] [Abstract][Full Text] [Related]
14. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis].
Bao Q; Wang K; Wang HW; Jin KM; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993
[No Abstract] [Full Text] [Related]
15. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.
Beppu T; Miyamoto Y; Sakamoto Y; Imai K; Nitta H; Hayashi H; Chikamoto A; Watanabe M; Ishiko T; Baba H
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S405-13. PubMed ID: 24570379
[TBL] [Abstract][Full Text] [Related]
16. A Prognostic Scoring System to Predict Survival Outcome of Resectable Colorectal Liver Metastases in this Modern Era.
Liu W; Zhang W; Xu Y; Li YH; Xing BC
Ann Surg Oncol; 2021 Nov; 28(12):7709-7718. PubMed ID: 34023948
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.
Chen Y; Chang W; Ren L; Chen J; Tang W; Liu T; Jian M; Liu Y; Wei Y; Xu J
Oncologist; 2020 Jul; 25(7):e1031-e1041. PubMed ID: 32181531
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer.
Peng J; Li W; Fan W; Zhang R; Li X; Xiao B; Dong Y; Wan D; Pan Z; Lin J; Wu X
Cancer Cell Int; 2021 Oct; 21(1):554. PubMed ID: 34688293
[TBL] [Abstract][Full Text] [Related]
19. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
